Research Holdings Revolutionizes Adult Orthodontics with Groundbreaking MART Treatment Protocol
- Taikang Bybo Dental's study reveals effective adult orthodontic treatment with Mandibular Advancement Repositioning Therapy (MART) for Class II malocclusion.
- The MART protocol includes two stages focusing on TMJ adaptation and optimal tooth positioning, enhancing non-invasive treatment options.
- This research emphasizes advanced technology in orthodontics, transforming treatment possibilities for adults previously considered unsuitable for functional therapies.
Revolutionizing Adult Orthodontics: A Breakthrough in Treatment Protocols
Recent advancements in orthodontic treatment for adults are set to change conventional perceptions, especially regarding the efficacy of functional therapies in non-growing patients. On December 5, 2025, Taikang Bybo Dental announces the publication of a groundbreaking clinical study in the Journal of Aligner Orthodontics, led by Professor Gang Shen’s Orthodontic Team. This study introduces the Mandibular Advancement Repositioning Therapy (MART) utilizing the S8-SGTB, a clear orthodontic appliance co-developed by Smartee Denti-Technology and Professor Shen's team. The findings challenge the long-standing notion that functional therapies are only appropriate for growing patients, providing compelling evidence that adult temporomandibular joints (TMJ) can adapt effectively to mandibular repositioning.
The research details a two-stage protocol for MART aimed at treating three-depth malocclusion in adult patients. In Stage I, the focus is on guiding the mandible to its optimal position while ensuring TMJ adaptation and early alignment. Stage II then addresses the completion of buccal space closure, refining intercuspation, coordinating midline alignment, and finalizing tooth positioning, all while maintaining vertical control—even in severe cases. Professor Shen underscores that this protocol offers a reliable, non-invasive treatment option for adult patients suffering from skeletal Class II malocclusion, a significant improvement in the landscape of orthodontic care. This innovative approach not only enhances treatment outcomes but also opens new avenues for adults who have historically been deemed unsuitable for similar functional corrections.
Moreover, the study's implications extend beyond immediate orthodontic practices. It highlights the importance of proper design and digital workflow in achieving predictable and sustainable functional corrections. As the industry shifts toward embracing advanced orthodontic technologies, the MART using the S8-SGTB stands out as a pioneering solution, empowering dental professionals to offer effective treatment plans tailored to adult patients. This breakthrough signals a paradigm shift in adult orthodontics, fostering new hope for a demographic previously overlooked in the context of functional therapies.
In related developments within the health sector, Biorep Technologies achieves a significant milestone with the independent human pancreatic islet isolation using its PRISM system. This marks the first successful application of the system outside its original institution, showcasing its reproducibility and potential for broader adoption in cell isolation workflows. Meanwhile, the American Academy of Orthopaedic Surgeons launches the Orthobiologics Registry to address data gaps in regenerative medicine for knee osteoarthritis, underscoring a growing emphasis on evidence-based practices across the health care landscape. Such initiatives reflect a broader trend toward enhancing patient care and outcomes through innovative research and robust clinical management strategies.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…